Skip to main content
. Author manuscript; available in PMC: 2021 Sep 1.
Published in final edited form as: Andrology. 2020 Jul 2;8(5):1324–1331. doi: 10.1111/andr.12834

Table 3 –

Estimated changes from baseline in circulating counts of erythrocytes, platelets and leukocytes for treatment groups in the OPTIMEN trial.

Treatment Group
Placebo 100mg TE Difference P-value
Erythrocyte count, 106 cells/μL 0.01 (−0.05, 0.07) 0.45 (0.38, 0.51) 0.44 (0.35, 0.53) <0.001
Platelets, 103cells/μL 2.64 (−4.24, 9.51) 8.94 (1.49, 16.4) 6.30 (−3.99, 16.6) 0.23
Leukocyte count, 103cells/μL 0.25 (0.01, 0.48) 0.77 (0.52, 1.03) 0.53 (0.18, 0.88) 0.004

Data are expressed as estimated change from baseline (95% Confidence Intervals). The P values, derived from the mixed-effects regression model with repeated measures framework, for the testosterone effect (testosterone vs placebo) are also shown. TE, testosterone enanthate